Product logins

Find logins to all Clarivate products below.


Eosinophilic Esophagitis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of eosinophilic esophagitis (EoE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of EoE for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s EoE forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of EoE?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of EoE over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts five EoE patient populations, as follows:

  • Diagnosed prevalent cases
  • Diagnosed prevalent cases by phenotypes
  • Diagnosed prevalent cases with comorbid allergic rhinitis
  • Diagnosed prevalent cases with comorbid asthma
  • Diagnosed prevalent cases with comorbid atopic dermatitis

Related Market Assessment Reports

Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
Report
Thyroid Eye Disease – Executive Insights – Thyroid Eye Disease | Executive Insights (US)
Report
Biosimilars – Current Treatment – Oncology
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…